Marinus Pharmaceuticals Inc. (MRNS) expects to make its recently approved ZTALMY commercially available in the U.S. through a specialty pharmacy beginning in July. ZTALMY oral suspension was approved by the FDA as recently as March 18 for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, a rare form of genetic epilepsy.
from RTT - Earnings https://ift.tt/n3ixbIy
via IFTTT
No comments:
Post a Comment